Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 11, 2009, Pages 1349-1361

  Reboldi, Gianpaolo ^a   Gentile, Giorgio ^a   Angeli, Fabio ^b   Verdecchia, Paolo ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Angiotensin II type 1 receptor blocker; Angiotensin converting enzyme inhibitor; Antihypertensive agent; Calcium channel blocker; Combination; Diabetes mellitus; Diuretic; Drug combination; Drug therapy; Hypertension

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL PLUS CHLORTALIDONE; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CILAZAPRIL; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; GLICLAZIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; INDAPAMIDE PLUS PERINDOPRIL; LERCANIDIPINE; MANIDIPINE; METOPROLOL; OLMESARTAN; PLACEBO; RAMIPRIL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL PLUS VERAPAMIL; UNINDEXED DRUG;

ADD ON THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; KIDNEY DISEASE; METABOLIC REGULATION; MICROANGIOPATHY; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DIURETICS; DRUG COMBINATIONS; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 73349142380     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.133     Document Type: Review

References (128)

1. Steinbrook R. Facing the diabetes epidemic - mandatory reporting of glycosylated hemoglobin values in New York City. N. Engl. J. Med. 354(6), 545-548 (2006).
2. Gan D. Diabetes Atlas. International Diabetes Federation, Brussels, Belgium (2003).
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047-1053 (2004).
4. Roglic G, Unwin N, Bennett PH et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 28(9), 2130-2135 (2005).
5. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37(4), 1053-1059 (2001).
6. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287(19), 2570-2581 (2002).
7. Stults B, Jones RE. Management of hypertension in diabetes. Diabetes Spectr. 19(1), 25-31 (2006).
8. Rosamond W, Flegal K, Friday G et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115(5), e69-e171 (2007).
9. Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int. J. Cardiol. 105(3), 315-318 (2005).
10. Tomson C, Ford D, Ansell D. The UK Renal Registry: an overview. Br. J. Hosp. Med. (Lond.) 69(10), 548-549 (2008).
11. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42(6), 1206-1252 (2003).
12. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25(6), 1105-1187 (2007).
13. American Diabetes Association SG. Standards of medical care in diabetes - 2008. Diabetes Care 31(Suppl. 1), S12-S54 (2008).
14. UKPDS SG. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317(7160), 703-713 (1998).
15. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 122(3), 290-300 (2009).
16. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326(7404), 1427 (2003).
17. Taylor AA. Combination drug treatment of hypertension: have we come full circle? Curr. Cardiol. Rep. 6(6), 421-426 (2004).
18. Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann. Intern. Med. 148(1), 16-29 (2008).
19. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358(24), 2545-2559 (2008).
20. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med. 358(24), 2560-2572 (2008).
21. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329(14), 977-986 (1993).
22. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with Type 1 diabetes four years after a trial of intensive therapy. N. Engl. J. Med. 342(6), 381-389 (2000).
23. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28(2), 103-117 (1995).
24. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 352(9131), 837-853 (1998).
25. UKPDS SG. Effect of intensive bloodglucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352(9131), 854-865 (1998).
26. MMWR WR. Racial differences in trends of end-stage renal disease, by primary diagnosis - United States, 1994-2004. MMWR Morb. Mortal. Wkly Rep. 56(11), 253-256 (2007).
27. Wilcox CS. Metabolic and adverse effects of diuretics. Semin. Nephrol. 19(6), 557-568 (1999).
28. Greenberg A. Diuretic complications. Am. J. Med. Sci. 319(1), 10-24 (2000).
29. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 48(2), 219-224 (2006).
30. Carter BL, Einhorn PT, Brands M et al. Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension 52(1), 30-36 (2008).
31. Opie L. Angiotensin-Converting Enzyme Inhibitors: the Advance Continues. 3rd Edition. University of Cape Town Press, South Africa, 64-67; 222-224 (1999).
32. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N. Engl. J. Med. 321(13), 868-873 (1989).
33. Vuorinen-Markkola H, Yki-Jarvinen H. Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism 44(1), 85-89 (1995).
34. Henriksen EJ, Jacob S. Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. Diabetes Obes. Metab. 5(4), 214-222 (2003).
35. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensinconverting enzyme inhibitors prevent diabetes and cardiovascular disease. Am. J. Cardiol. 91(12A), 30H-37H (2003).
36. Scheen AJ. Renin-angiotensin system inhibition prevents Type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab. 30(6), 498-505 (2004).
37. Blendea MC, Jacobs D, Stump CS et al. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am. J. Physiol. Endocrinol. Metab. 288(2), E353-E359 (2005).
38. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferatoractivated receptor-γ activity. Circulation 109(17), 2054-2057 (2004).
39. Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset Type 2 diabetes. Diabetes Care 28(9), 2261-2266 (2005).
40. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369(9557), 201-207 (2007).
41. Weinberger MH. Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension 5(5 Pt 2), III132-III138 (1983).
42. Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. J. Cardiovasc. Pharmacol. 7(Suppl. 1), S52-S55 (1985).
43. Parati G, omboni S, Malacco E. Antihypertensive efficacy of zofenopril and hydrochlorothiazide and their different combinations assessed by 24h ambulatory blood pressure monitoring. J. Hypertens. 2(Suppl.), S309 (2005).
44. Eriksson JW, Jansson PA, Carlberg B et al. Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the Mechanisms for the Diabetes Preventing Effect of Candesartan (MEDICA) study. Hypertension 52(6), 1030-1037 (2008).
45. Shamiss A, Carroll J, Peleg E, Grossman E, Rosenthal T. The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. Am. J. Hypertens. 8(3), 276-281 (1995).
46. Hunter SJ, Wiggam MI, Ennis CN et al. Comparison of effects of captopril used either alone or in combination with a thiazide diuretic on insulin action in hypertensive Type 2 diabetic patients: a double-blind crossover study. Diabet. Med. 16(6), 482-487 (1999).
47. McLaughlin DM, Atkinson AB, Ennis CN et al. Comparison of effects of combined ACE inhibitor and low-dose thiazide diuretic with ACE inhibitor alone on insulin action in patients with hypertension and Type 2 diabetes: a double-blind crossover study. Diabet. Med. 25(5), 631-634 (2008).
48. Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370(9590), 829-840 (2007).
49. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366(9489), 895-906 (2005).
50. Bakris G, Molitch M, Hewkin A et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 29(12), 2592-2597 (2006).
51. Fogari R, Derosa G, Zoppi A et al. Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Intern. Med. 47(5), 361-366 (2008).
52. Fernandez R, Puig JG, Rodriguez-Perez JC, Garrido J, Redon J. Effect of two antihypertensive combinations on metabolic control in Type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J. Hum. Hypertens. 15(12), 849-856 (2001). • In 103 hypertensive and microalbuminuric diabetics enrolled in the Trandolapril-Verapamil in Non-insulin Dependent Diabetics (TRAVEND) trial, the acetyl choline esterase/calcium channel blockers combination allowed a better metabolic control than the ACE/diuretic combination.
53. Holzgreve H, Nakov R, Beck K, Janka HU. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am. J. Hypertens. 16(5 Pt 1), 381-386 (2003).
54. Fogari R, Derosa G, Zoppi A et al. Effects of manidipine/delapril versus olmesartan/ hydrochlorothiazide combination therapy in elderly hypertensive patients with Type 2 diabetes mellitus. Hypertens. Res. 31(1), 43-50 (2008).
55. Baron AD, Brechtel G, Wallace P, Edelman SV. Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am. J. Physiol. 255(6 Pt 1), E769-E774 (1988).
56. Draznin B, Sussman KE, Eckel RH, Kao M, Yost T, Sherman NA. Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J. Clin. Invest. 82(6), 1848-1852 (1988).
57. Bell DS. β-adrenergic blocking agents in patients with diabetes - friend and foe. Endocr. Pract. 5(1), 51-53 (1999).
58. Giugliano D, Acampora R, Marfella R et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulindependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann. Intern. Med. 126(12), 955-959 (1997).
59. Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with Type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292(18), 2227-2236 (2004). • In hypertensive diabetics of the large Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial, the mean glycosylated hemoglobin (HBA1c) increased with traditional β-blocker metoprolol, whereas newer β-blocker carvedilol caused no adverse metabolic effects.
60. Jonas M, Reicher-Reiss H, Boyko V et al. Usefulness of β-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am. J. Cardiol. 77(15), 1273-1277 (1996).
61. Sharma AM, Davidson J, Koval S, Lacourciere Y. Telmisartan/ hydrochlorothiazide versus valsartan/ hydrochlorothiazide in obese hypertensive patients with Type 2 diabetes: the SMOOTH study. Cardiovasc. Diabetol. 6, 28 (2007).
62. Elliot WJ. Cyclic and circadian variations in cardiovascular events. Am. J. Hypertens. 14(9 Pt 2), 291S-295S (2001).
63. Sowers JR, Neutel JM, Saunders E et al. Antihypertensive efficacy ofiIrbesartan/ HCTZ in men and women with the metabolic syndrome and Type 2 diabetes. J. Clin. Hypertens. (Greenwich) 8(7), 470-480 (2006).
64. Lewin AJ, Weir MR. Antihypertensive efficacy and tolerability of irbesartan/ hydrochlorothiazide in hypertensive patients stratified by body mass index and Type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/ HCTZ Blood Pressure Reductions in Diverse Patient Populations trial. Clin. Ther. 30(12), 2354-2365 (2008).
65. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351(9118), 1755-1762 (1998).
66. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359(9311), 1004-1010 (2002).
67. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363(9426), 2022-2031 (2004).
68. McFarlane SI, Castro J, Kaur J et al. Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J. Clin. Hypertens. (Greenwich) 7(2), 73-80 (2005).
69. Sowers JR, Lastra G, Rocha R, Seifu Y, Crikelair N, Levy DG. Initial combination therapy compared with monotherapy in diabetic hypertensive patients. J. Clin. Hypertens. (Greenwich) 10(9), 668-676 (2008).
70. 2+. Antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. Diabetes Care 14(10), 911-914 (1991).
71. Fogari R, Preti P, Lazzari P et al. Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients. Eur. J. Clin. Pharmacol. 59(4), 271-275 (2003).
72. Mugellini A, Preti P, Zoppi A et al. Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with Type II diabetes mellitus. J. Hum. Hypertens. 18(10), 687-691 (2004).
73. Bakris GL, Weir MR. Achieving goal blood pressure in patients with Type 2 diabetes: conventional versus fixed-dose combination approaches. J. Clin. Hypertens. (Greenwich) 5(3), 202-209 (2003).
74. Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J. Hypertens. 24(1), 185-192 (2006).
75. Tobe S, Kawecka-Jaszcz K, Zannad F, Vetrovec G, Patni R, Shi H. Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial. J. Clin. Hypertens. (Greenwich) 9(2), 120-127 (2007).
76. Roca-Cusachs A, Schmieder RE, Triposkiadis F et al. Efficacy of manidipine/delapril versus losartan/ hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. J. Hypertens. 26(4), 813-818 (2008).
77. Katayama S, Kawamori R, Iwamoto Y, Saito I, Kuramoto K. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with Type 2 diabetes (ATTEST) study. Hypertens. Res. 31(8), 1499-1508 (2008).
78. Kloner RA, Neutel J, Roth EM et al. Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial. Ann. Pharmacother. 42(11), 1552-1562 (2008).
79. Uresin Y, Taylor AA, Kilo C et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J. Renin-Angiotensin-Aldosterone System 8(4), 190-200 (2007).
80. Taylor A, Tschope D, Kilo C, Ibram G, Fang H, Satlin A. Adding aliskiren to ramipril improves 24-hour blood pressure control compared to ramipril alone in patients with diabetes and hypertension. J. Hypertens. 24(Suppl. 4), S81. Abstract P84.268 (2006).
81. Rachmani R, Levi Z, Slavachevsky I, Half-Onn E, Ravid M. Effect of an α-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in Type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. Nephron 80(2), 175-182 (1998).
82. Mogensen CE, Viberti G, Halimi S et al. Effect of Low-Dose Perindopril/ Indapamide on Albuminuria in Diabetes: Preterax in Albuminuria Regression: PREMIER. Hypertension 41(5), 1063-1071 (2003).
83. PROGRESS SG. Effects of a perindoprilbased blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur. Heart J. 24(5), 475-484 (2003).
84. Berthet K, Neal BC, Chalmers JP et al. Reductions in the risks of recurrent stroke in patients with and without diabetes: The PROGRESS Trial. Blood Pressure 13(1), 7-13 (2004).
85. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21(4), 597-603 (1998).
86. Nosadini R, Tonolo G. Cardiovascular and renal protection in Type 2 diabetes mellitus: the role of calcium channel blockers. J. Am. Soc. Nephrol. 13(Suppl. 3), S216-S223 (2002).
87. Tuomilehto J, Rastenyte D, Birkenhager WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N. Engl. J. Med. 340(9), 677-684 (1999).
88. Bakris GL, Gaxiola E, Messerli FH et al. Clinical Outcomes in the Diabetes Cohort of the International Verapamil SRTrandolapril Study. Hypertension 44(5), 637-642 (2004).
89. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in Type 2 diabetes. N. Engl. J. Med. 351(19), 1941-1951 (2004).
90. Ostergren J, Poulter NR, Sever PS et al. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with Type II diabetes. J. Hypertens. 26(11), 2103-2111 (2008).
91. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359(23), 2417-2428 (2008). •• The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial demonstrated a striking superiority of the benazepril/amlodipine combination, as compared with benazepril/ hydrochlorothiazide (HCTZ), in reducing cardiovascular (CV) events in highcardiovascular risk hypertensives, 60% of whom were diabetics.
92. Chobanian AV. Does it matter how hypertension is controlled? N. Engl. J. Med. 359(23), 2485-2488 (2008).
93. Aguilar D, Solomon SD, Kober L et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 110(12), 1572-1578 (2004).
94. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358(15), 1547-1559 (2008). •• In patients at high CV risk of the ONTARGET trial, ACE/ARB combination therapy did not offer an additional reduction in the primary composite end point (death from CV causes, myocardial infarction, stroke, or hospitalization for heart failure) compared with ramipril, but significantly increased the risk of adverse events.
95. de Pablos-Velasco PL, Pazos Toral F, Esmatjes JE et al. Losartan titration versus diuretic combination in Type 2 diabetic patients. J. Hypertens. 20(4), 715-719 (2002).
96. Chan JC, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ 305(6860), 981-985 (1992).
97. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 54(4), 1283-1289 (1998).
98. Fogari R, Preti P, Zoppi A et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive Type 2 diabetic patients. Am. J. Hypertens. 15(12), 1042-1049 (2002).
99. Winer N, Folker A, Murphy JA et al. Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with Type 2 diabetes. Prev. Cardiol. 8(2), 87-92 (2005).
100. Krimholtz MJ, Karalliedde J, Thomas S, Bilous R, Viberti G. Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease. J. Am. Soc. Nephrol. 16(Suppl. 1), S42-S47 (2005).
101. Nakamura T, Inoue T, Fujiwara N et al. Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy. Clin. Nephrol. 70(5), 385-392 (2008).
102. Martinez-Martin FJ, Saiz-Satjes M. Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. Expert Rev. Cardiovasc. Ther. 6(10), 1347-1355 (2008).
103. Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T. Disparate effects of calcium antagonists on renal microcirculation. Hypertens. Res. 19(1), 31-36 (1996).
104. Hayashi K, Ozawa Y, Fujiwara K, Wakino S, Kumagai H, Saruta T. Role of actions of calcium antagonists on efferent arterioles - with special references to glomerular hypertension. Am. J. Nephrol. 23(4), 229-244 (2003).
105. 2+ channel subtypes and pharmacology in the kidney. Circ. Res. 100(3), 342-353 (2007).
106. Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 73(11), 1303-1309 (2008). •• In microalbuminuric hypertensive diabetics of the Gauging Albuminuria Reduction with Lotrel in Diabetic Patients with Hypertension (GUARD) trial, rates of progression to overt diabetic nephropathy were similar between the benazepril/amlodipine and the benazepril/hydrochlorothiazide group, but the mean decrease in the estimated glomerular filtration rate over the 52-week period was less in the benazepril/ amlodipine group than in the benazepril/ hydrochlorothiazide group.
107. Fogari R, Corradi L, Zoppi A et al. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with Type II diabetes and microalbuminuria. Am. J. Hypertens. 20(10), 1092-1096 (2007).
108. Fogari R, Derosa G, Zoppi A et al. Effect of telmisartan- amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am. J. Hypertens. 20(4), 417-422 (2007).
109. Mann JFE, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372(9638), 547-553 (2008). • In the ONTARGET trial, ACE/ARB combination allowed a greater reduction in urinary albumin/creatinine ratio, but such reduction did not translate into an overall lower rate of renal events.
110. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann. Intern. Med. 148(1), 30-48 (2008).
111. Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet. Med. 24(5), 486-493 (2007).
112. Tutuncu NB, Gurlek A, Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetol. 38(4), 157-161 (2001).
113. Andersen NH, Poulsen PL, Knudsen ST et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 28(2), 273-277 (2005).
114. Saklayen MG, Gyebi LK, Tasosa J, Yap J. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. J. Investig. Med. 56(4), 714-719 (2008).
115. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in Type 2 diabetes and nephropathy. N. Engl. J. Med. 358(23), 2433-2446 (2008).
116. Ingelfinger JR. Aliskiren and dual therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 358(23), 2503-2505 (2008).
117. Pedersen MM, Hansen KW, Schmitz A, Sorensen K, Christensen CK, Mogensen CE. Effects of ACE inhibition supplementary to β blockers and diuretics in early diabetic nephropathy. Kidney Int. 41(4), 883-890 (1992).
118. Jawa A, Nachimuthu S, Pendergrass M, Asnani S, Fonseca V. β-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. J. Diabetes Complications 22(5), 303-308 (2008).
119. Sowers JR. Treatment of hypertension in patients with diabetes. Arch. Intern. Med. 164(17), 1850-1857 (2004).
120. Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 25(1), 134-147 (2002).
121. Turnbull F, Neal B, Algert C et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med. 165(12), 1410-1419 (2005).
122. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 49(1), 69-75 (2007).
123. Kasiske BL. Relationship between vascular disease and age-associated changes in the human kidney. Kidney Int. 31(5), 1153-1159 (1987).
124. Halimi JM, Mimran A. ONTARGET: does dual blockade of the reninangiotensin system provide more effective cardiovascular and renal protection in patients at high cardiovascular risk? Curr. Hypertens. Rep. 11(2), 85-87 (2009).
125. Berns JS. Is angiotensin-converting enzyme inhibitor and angiotensin receptor blocker combination therapy better than monotherapy and safe in patients with CKD? Am. J. Kidney Dis. 53(2), 192-196 (2009).
126. Reboldi G, Gentile G, Angeli F, Verdecchia P. Choice of ACE inhibitor combinations in hypertensive patients with Type 2 diabetes: update after recent clinical trials. Vasc. Health Risk Manag. 5(1), 411-427 (2009).
127. Oregon Evidence-based Practice Center OHaSU. Drug class review on ACE inhibitors (2008). www.rx.wa.gov/documents/acei-scan.pdf,
128. Oregon Evidence-based Practice Center OHaSU. Drug class review on angiotensin II receptor antagonists. Final Report (2006). www.ohsu.edu/ohsuedu/ research/policycenter/customcf/derp/product/AIIRA-Final-Report-Update%2013.pdf